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Abstract
Background: There is limited evidence about the effectiveness of varenicline and nicotine
replacement therapy (NRT) for long-term smoking cessation in primary care, or whether
the treatment effectiveness differs by socioeconomic position (SEP). Therefore, we esti-
mated the long-term effectiveness of varenicline versus NRT (> 2 years) on smoking ces-
sation, and investigated whether effectiveness differs by SEP.
Methods: This is a prospective cohort study of electronic medical records from 654 gen-
eral practices in England, within the Clinical Practice Research Datalink, using three dif-
ferent analytical methods: multivariable logistic regression, propensity score matching
and instrumental variable analyses. Exposure was prescription of varenicline versus
NRT, and the primary outcome was smoking cessation at 2 years’ follow-up; outcome
was also assessed at 3, 6, and 9 months, and at 1 and 4 years after exposure. SEP was
defined using the Index of Multiple Deprivation.
Results: At 2 years, 28.8% (N¼ 20 362/70 610) of participants prescribed varenicline and
24.3% (N¼ 36 268/149 526) of those prescribed NRT quit; adjusted odds ratio was 1.26
[95% confidence interval (CI): 1.23 to 1.29], P<0.0001. The association persisted for up to
4 years and was consistent across all analyses. We found little evidence that the effect-
iveness of varenicline differed greatly by SEP. However, patients from areas of higher
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deprivation were less likely to be prescribed varenicline; adjusted odds ratio was 0.91
(95% CI: 0.90 to 0.92), P<0.0001.
Conclusions: Patients prescribed varenicline were more likely to be abstinent up to
4 years after first prescription than those prescribed NRT. In combination with other evi-
dence, the results from this study may be used to update clinical guidelines on the use of
varenicline for smoking cessation.
Key words: Smoking cessation, tobacco, varenicline, nicotine replacement therapy, effectiveness, primary care,
causal, instrumental variable, cohort, electronic medical records
Introduction
Tobacco is the world’s leading preventable cause of serious
illness and premature death.1 One in two smokers will die
from their addiction unless they stop smoking.2 To date,
there are only three full-scale randomized controlled trials
(RCTs) which have compared the effects of varenicline and
nicotine replacement therapy (NRT) on smoking cessa-
tion.3–6 Baker and colleagues found that varenicline had
similar effects as did NRT on smoking abstinence at
26 weeks; the odds ratio was 1.3 (95% confidence interval,
0.9 to 1.9).3 Aubin and colleagues also reported similar ef-
fects between the two medicines at 12 months [1.4 (95%
confidence interval 0.99 to 1.99)].4 In contrast, Anthenelli
and colleagues (2016) reported that those treated with var-
enicline achieved higher rates of abstinence compared with
NRT at 24 weeks; odds ratio (and 95% confidence inter-
val) were 1.5 (1.3 to 1.8).5 Cahill and colleagues conducted
a network meta-analysis of RCTs which suggested that
varenicline is the most efficacious smoking cessation medi-
cine at up to 12 months; odds ratio (and 95% confidence
interval) were 1.6 (1.3 to 1.9).7 However, the efficacy of
treatments in trial settings may differ from their effective-
ness in everyday clinical settings because of variation in
treatment delivery and participant characteristics.
Moreover, abstinence at 6 to 12 months does not necessar-
ily guarantee longer-term abstinence (> 24 months). A sys-
tematic review of RCTs found that 30% of participants
recorded as quitting at 12 month follow-up relapsed in
subsequent years.8
Furthermore, we do not know whether the effectiveness
of smoking cessation medications differs by socioeconomic
position (SEP). Smoking is a major contributor to health
inequalities between the richest and poorest in society.9,10
There is evidence that smokers in more deprived areas in the
UK are more likely to receive advice to quit from their gen-
eral practitioner.11 Nevertheless, observational studies have
found that smokers from disadvantaged backgrounds are
much less likely quit,10 even after accessing treatment from
specialist stop-smoking services.12 However, there is little evi-
dence from RCTs about whether the effectiveness of smoking
cessation medications differs by SEP, and trials are typically
underpowered to detect treatment effect heterogeneity.
In this study we aimed to: (i) estimate the long-term ef-
fectiveness of prescribing varenicline versus NRT on smok-
ing cessation in primary care; and (ii) examine whether the
effectiveness differed by SEP.
Methods
We conducted a prospective cohort study using electronic
medical records from 654 general practices in England. This
research was conducted according to the principles of the
Declaration of Helsinki and we followed STROBE reporting
guidelines.13 The study protocol was published in advance14
and is available via the Open Science Framework (https://
osf.io/g9ch2/) and ClinicalTrials.gov (ID:NCT02681848). It
was approved by the Independent Scientific Advisory
Committee (ISAC) for MHRA Database Research (https://
www.cprd.com/isac/) (protocol number: 15_107R).
Data source and population
We obtained data from the Clinical Practice Research
Datalink (CPRD) GOLD [www.cprd.com], a medical
Key Messages
• This is the largest study to date investigating the effectiveness of varenicline versus NRT for smoking cessation in pri-
mary care settings.
• Varenicline is more effective than NRT for smoking cessation up for to 4 years in primary care settings.
• Varenicline’s effectiveness does not appear to be altered by socioeconomic position.
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database containing data on over 13 million patients
across the UK. Registered patients are representative of the
UK’s demography.15
Code lists
We defined variables using medical and product codes
within the CPRD. Validated lists were used where avail-
able, and where unavailable, code lists were agreed upon
by field experts (R.M.M., D.R., K.H.T.) and by using
the British National Formulary and the International
Classification of Diseases. Code lists are available at
[https://github.com/nmdavies/varenicline effectiveness/].
Patients
Included patients were aged 18 years and over, and were
prescribed NRT or varenicline. We included patients with
no breaks in their records, with complete information on
year of birth, registration date and sex; and patients from
practices with continuous recording of data. We excluded
patients who registered with their practice within 365 days
of their first recorded prescription, to ensure availability of
baseline data and data to define the first prescription of
smoking cessation medication.
Variables
Exposure
Treatment was defined as prescription of varenicline, and
control as prescription of NRT (e.g. patches, gum, loz-
enges, sprays and inhalers). Prescriptions used to define
treatment groups occurred after 1 September 1 2006 until
30 September 30 2015, with no previous evidence of use of
a related product during 18 months before the first pre-
scription was issued. We used the first treatment episode16
to ensure that exposure groups were ‘new users’ of the
medication and time of treatment allocation was similar to
baseline in a clinical trial, which is the time of randomiza-
tion.17 We did not model treatment switching because this
is likely to be strongly related to patient characteristics.
Outcome
The primary outcome was having an electronic medical
record indicating smoking at 2-year follow-up. Smoking
status was also assessed at 3, 6 and 9 months, and at 1 and
4 years after the first prescription. GPs recorded their pa-
tients’ smoking status as current, former or never smoker
in their electronic medical records; these data were repeat-
edly recorded over time as part of a UK nationwide
incentive programme,18 and these smoking records are
highly comparable to smoking prevalence as reported in
representative population surveys.19 We determined each
patient’s smoking status by using their most recent smok-
ing record identified between cohort entry and each
follow-up period (e.g. 3 months, 6 months, 1 year). In our
primary analysis, patients with missing smoking data were
assumed to be continuing smokers.20 For statistical ana-
lyses, smoking status was defined as smoker (0) or quit (1).
Covariates
Covariates included patients’ age at time of prescription,
sex, days registered in the CPRD, mental health history (bi-
polar, depression, neurotic, anxiety disorders, self-harm or
other mental health disorders), previous use of psycho-
tropic medications (antidepressants, antipsychotics, hyp-
notics/anxiolytics or other psychotropic medications), drug
or alcohol misuse,21 mean number of GP visits 1 year pre-
ceding first prescription, body mass index (BMI), SEP and
major chronic illness (Charlson Index22). SEP was recorded
based on patient postcode at the lower-layer super-output
area level, and measured using the index of multiple de-
privation (IMD) which is the official measure of depriv-
ation in England; and was recorded using twentiles (i.e.
1¼ lowest level of deprivation, 20¼ highest level).
Follow up
Patients were followed up at 3, 6, and 9 months and 1, 2
and 4 years after exposure.
Statistical analysis
Analyses were conducted using Stata 14. All scripts are
available online [https://github.com/nmdavies/varenicline
effectiveness/]. To investigate the effects of varenicline ver-
sus NRT on smoking cessation, we conducted a multivari-
able adjusted logistic regression. Models were estimated
using cluster robust standard errors, which accounted for
potential clustering of patients between physicians.
Differences in the effectiveness of varenicline by SEP were
investigated by stratifying patients on level of deprivation
non-imputed data, low deprivation as indicated by an IMD
rank of 1 to 10, and high deprivation as indicated by an
IMD score of 11 to 20, and conducting partially adjusted
logistic regression models for age, sex and year of smoking
cessation medication prescription (see Supplementary
Methods for further details, available as Supplementary
data at IJE online).
To address potential residual confounding and selection
bias (i.e. varenicline users may have previously had a failed
a quit attempt using NRT, and thus are more likely to have
been prescribed varenicline), we repeated all analyses
using: propensity score matched logistic regressions; and
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instrumental variable regressions using physicians’ pre-
scribing preferences as the instrument.23 Instrumental vari-
able analysis uses variables which are: related to the
exposure, independent of confounders, and have no direct
effects on the outcome.24 If the multivariable adjusted re-
gression results suffer from residual confounding, they will
differ compared with results from the instrumental vari-
able models (see Supplementary material for further details
of the methods, available as Supplementary data at IJE on-
line). We examined the extent of confounding variables
across all three analysis types (e.g. association between the
exposure or instrument, and baseline covariates).25–28
Missing baseline covariate data
To increase efficiency and minimize selection bias, we used
multivariable multiple imputation to impute data for pa-
tients missing BMI and IMD values.29 The imputation pro-
cedure produced 20 imputed datasets, and the imputation
model included all exposures and covariates.30
Sensitivity analysis: missing outcome data
It was possible that our ascertainment of outcome, i.e. in
which participants with missing smoking status medical re-
cords were classed as continuing smokers,20 might lead to mis-
classification bias. To examine this possibility we conducted a
sensitivity analysis in which we imputed missing outcome data
using multivariate multiple imputation. The imputation pro-
cedure produced 20 imputed datasets, and the imputation
model included all exposures and covariates.30 We compared
the effect estimates derived from the sensitivity analysis (miss-
ing outcome data¼ imputed) with those derived from the
main analysis (missing outcome data¼ continuing smoker).
Comparison with other studies
We used a random effects meta-analysis to compare our
multivariable logistic regression estimate with estimates re-
ported by the systematic review and those derived from sub-
sequently published RCTs of varenicline versus NRT.3–5,7
Results
Population characteristics
A total of 287 079 patients were prescribed smoking
cessation medications during the study period. Of
these, 149 526 patients prescribed NRT and 70 610
patients prescribed varenicline were eligible for analysis.
Supplementary Figure 1 (available as Supplementary data
at IJE online) presents the number of patients excluded
and reasons for exclusion.14 Of those prescribed NRT, a
range of products was prescribed including patches, gum,
oral spray, nasal spray, oral film, inhaler, lozenges and
microtab (see Supplementary Table 1, available as
Supplementary data at IJE online, for list of NRT products
prescribed); 34 396 (23%) of the patients prescribed NRT
were prescribed more than one nicotine product. On aver-
age, patients who were prescribed varenicline were issued
2.8 [standard deviation (SD) ¼ 1.6] prescriptions for vareni-
cline in the 3 months following their first eligible prescrip-
tion, and received an average of 107.5 (SD¼ 120.7) tablets;
49.7% (N¼ 35 076/70 610) of these patients received a full
course of varenicline (i.e. 12 weeks) (Chapter 4, British
National Formulary). Patients who were initially prescribed
NRT were issued 2.5 (SD¼ 2.2) prescriptions for NRT on
average during the 3 months after their first eligible prescrip-
tion. At the time of prescription, patients’ mean age was
45.8 years (SD¼14.9); 52.6% of the cohort were women.
Baseline data indicated that this cohort was similar to other
studies of smokers from the UK and other developed na-
tions.21 The median patient had an IMD score of 12, indi-
cating that they lived in the 60–65% most deprived areas in
England (Table 1); 35.8% of patients showed evidence of a
major comorbidity.22 The number of patients with mental
health morbidities or prescribed psychotropic medications
was consistent with the prevalence of mental illness found in
cohorts of smokers.31 Patients prescribed NRT were more
likely to be older and to have a history of comorbidities.
The association of varenicline or NRT
prescriptions and smoking cessation
Patients prescribed varenicline were more likely to quit
smoking than those prescribed NRT, at all follow-ups
(Figure 1). Partially and fully adjusted multivariable regres-
sion models indicated that varenicline was associated with
increased odds of quitting smoking at all follow-ups, and
the association attenuated slightly at 4-year follow-up;
however, the direction and precision of the association re-
mained consistent over time (Figure 2). Table 2 presents
fully and partially adjusted odds ratios and 95% confi-
dence intervals for the association, by prescription and
follow-up. At 2 years, 28.8% (N¼ 20 362/70 610) of par-
ticipants prescribed varenicline quit, and 24.3%
(N¼ 36 268/149 526) of those prescribed NRT quit; the
fully adjusted odds ratio and 95% confidence interval at 2-
year follow-up were 1.26 (1.23 to 1.29), P< 0.001.
The propensity score balanced the treatment groups’
baseline covariates (see Supplementary Figures 2 and 3 for
bias assessment, available as Supplementary data at IJE
online), and in the instrumental variable model we found
that the instrument was more weakly associated with
the covariates than the patients’ actual prescription
(see Supplementary Figure 4, available as Supplementary
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data at IJE online, for bias assessment). Furthermore, the
propensity score matched and instrumental variable mod-
els estimates were entirely consistent with the fully
adjusted logistic regression estimates (see Supplementary
Tables 3 and 4 and Supplementary Figure 5, available as
Supplementary data at IJE online).
Differences in the effects of varenicline by SEP
In our sample, patients from the most deprived areas were
less likely to be prescribed varenicline compared with those
from the least deprived areas [age- and sex-adjusted odds
ratio 0.91 (95% confidence interval: 0.90 to 0.92),
P< 0.0001 (Supplementary Figure 6, available as
Figure 1. Absolute quit rates by treatment group at 3, 6 and 9 months and 1, 2 and 4 years after exposure, N¼ 220 136.
Table 1. Baseline characteristics of cohort and by exposure group. Data are the number (%) of patients unless otherwise
specified
Characteristic NRT (N¼149526) Varenicline
(N¼70610)
Whole sample
(N¼220136)
Age at time of first prescriptiona 46.4 (15.4) 44.5 (13.2) 45.8 (14.9)
Sex (female) 53.7% (80 348) 50.2% (35 466) 52.6% (115 814)
Index of multiple deprivation score (IMD)†b 12 12 12
Mean number of GP visits 1 year before first prescriptiona 7.9 (7.4) 6.3 (6.1) 7.4 (7.0)
BMI†a 26.4 (6.4) 26.5 (5.9) 26.4 (6.1)
Year of first prescriptionb 2009 2010 2009
Days of historya 3158.7 (1892.1) 3283.9 (1976.6) 3198.9 (1920.5)
Comorbidity ever (Charlson Index22) 37.6% (56 274) 31.9% (22 523) 35.8% (78 797)
Alcohol misuse ever 8.3% (12 422) 6.0 (4 199) 7.6% (16 621)
Drug misuse ever 3.1% (4 595) 1.9% (1 357) 2.7% (5 952)
Bipolar ever 1% (1 464) < 1% (160) < 1% (1 624)
Depression ever 35.0% (52 233) 29.2% (20 615) 33.1% (72 848)
Neurotic disorder ever 24.7% (36 921) 20.1% (14 189) 23.2% (51 110)
Self-harm ever 10.6% (15 903) 8.7% (6 169) 10.0% (22 072)
Other rare mental disorder ever 6.9% (10 343) 4.0% (2 832) 6.0% (13 175)
Antidepressant prescription ever 50.1% (74 921) 43.1% (30 435) 47.9% (105 356)
Antipsychotic prescription ever 20.0% (29 873) 14.8% (10 459) 18.3% (40 332)
Hypnotics/anxiolytics prescription ever 21.1% (31 513) 17.6% (12 415) 20.0% (43 928)
Other psychotropic medication < 1% (473) < 1% (120) < 1% (593)
Missing BMI and IMD values were imputed using multiple imputation.29 See Supplementary material for comparison of imputed and raw data, available as
Supplementary data at IJE online (Supplementary Table 2).
†Missing data: BMI data were missing for 14.2% (N¼ 31169); IMD data were missing for 43.3% (N¼ 95 355).
aData presented are mean and standard deviation.
bData presented are median.
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Supplementary data at IJE online]. Varenicline was slightly
more effective in patients from the least deprived areas at 3
months to 1 year after first prescription, but this difference
attenuated by the 2 and 4 years’ follow-up, as shown in
Figure 3 and Supplementary Tables 5 and 6 (available
as Supplementary data at IJE online).
Sensitivity analyses
The proportions of missing data were similar between ex-
posure groups at all follow-ups (Supplementary Table 7,
available as Supplementary data at IJE online). At 2 year’s
follow-up, 20.3% (44 737/220 136) of patients were miss-
ing smoking status data; these patients were on average,
younger, male, visited the GP fewer times per year and had
fewer comorbidities (Supplementary Table 8, available as
Supplementary data at IJE online). Effect estimates derived
from the main analysis (missing outcome data¼ continuing
smoker) were similar to estimates derived from models in
which missing outcome data were imputed (Supplementary
Table 9 and Supplementary Figure 7, available as
Supplementary data at IJE online).
Comparison with other studies
Our meta-analysis indicated that 6-month effectiveness
estimates derived from this study were similar to effect esti-
mates derived from full-scale RCTs and a network meta-
analysis, as indicated by heterogeneity statistics (Q¼ 6.42,
P¼ 0.170, I2¼ 37.7%, Tau2¼ 0.0084).32,33 Figure 4 indi-
cates that on average varenicline was associated with
higher abstinence rates compared with NRT [odds ratio
1.4 (95% confidence interval: 1.3 to 1.6] (Figure 4).
Discussion
Main findings
To date there are only three full-sized RCTs testing the
relative efficacy of NRT and varenicline,3–5 two of which
were open label,3,4 and all of which were limited to 6 to 12
months’ follow-up. These trials tell us little about the
longer-term differences in abstinence rates caused by these
medications.8 Second, there is little evidence about
whether varenicline is effective in disadvantaged popula-
tions. This is the largest study of the effectiveness of vareni-
cline versus NRT for enduring smoking cessation in
primary care settings.34,35 We found that patients pre-
scribed varenicline were more likely to quit smoking com-
pared with patients prescribed NRT. This difference
persisted over time, lasting up to 4 years, and the results
were consistent across three different analysis methods.
There was little evidence that varenicline’s effectiveness
differed by level of deprivation; however, patients from
more disadvantaged areas were less likely to be prescribed
varenicline.
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Figure 2. The association of prescribing varenicline and smoking cessa-
tion at 3,6 and 9 months and 1, 2 and 4 years after first prescription.
Fully multivariable adjusted logistic regression model: odds ratio and
95% confidence intervals presented. The difference in smoking cessa-
tion rates peaks at 6 months and declines over the following 3.5 years,
N ¼ 220 136.
Table 2. Multivariable logistic regression models: partial and fully adjusted odds ratios and 95% confidence intervals for the as-
sociation between varenicline versus NRT and smoking cessation at 3, 6 and 9 months and 1, 2 and 4 years after exposure,
N¼ 220136a
Model 3 months 6 months 9 months 1 year 2 years 4 years
Odds ratio (95% confidence interval)
Partial adjustedb 1.47 1.50 1.44 1.38 1.30 1.23
(1.42 to 1.52) (1.46 to 1.55) (1.40 to 1.48) (1.35 to 1.42) (1.27 to 1.33) (1.21 to 1.26)
Fully adjustedc 1.42 1.46 1.40 1.34 1.26 1.19
(1.38 to 1.47) (1.42 to 1.50) (1.36 to 1.44) (1.31 to 1.38) (1.23 to 1.29) (1.16 to 1.21)
aMissing BMI and IMD values were imputed using multiple imputation.29
bPartial adjusted models were adjusted for: age, sex and year of prescription.
cFully adjusted models were adjusted for: age, sex, days in history, IMD, number of GP visits 1 year preceding first prescription, BMI, year of first prescription,
history of major physical morbidity (Charlson Index), alcohol misuse, drug misuse, bipolar, depression, neurotic disorder, self-harm, other mental disorder, anti-
depressant prescription ever, antipsychotic prescription ever, hypnotics/anxiolytics prescription ever, other psychotropic medication.
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Strengths and limitations
Data from the CPRD are representative of the UK popula-
tion36 and are typical of smokers from other developed na-
tions;21,22,31 therefore these findings are likely to be
generalizable. Misclassification of outcome and exposure
is a major source of bias in observational studies.13 In this
study, the exposure, smoking cessation medication, was
defined using pre-existing and peer reviewed code lists.21
The outcome, smoking status, was well reported within the
CPRD11 and was defined using expert reviewed defin-
itions. Nevertheless, it is possible that some patients’ smok-
ing status was inconsistently recorded. We defined
smoking status using each patient’s latest smoking record
within each follow-up period. In our primary analysis, we
classified smokers with missing records as continuing
smokers. Our findings were similar in a sensitivity analysis
in which we imputed the outcome using multiple imput-
ation. Most covariate data were complete, and we used
multivariable multiple imputation to impute missing values
for the exceptions (IMD and BMI).29,30
Residual confounding is a major limitation of observa-
tional studies.24,37 A particular strength of this study was
the use of three different analytical methods to estimate the
effectiveness of varenicline. The propensity score balanced
the treatment groups’ observed baseline characteristics,
and produced similar findings to the multivariable adjusted
regression. Our instrumental variable analyses used natur-
ally occurring variation in the GPs’ prescribing which, if its
assumptions hold, is robust to unmeasured residual con-
founding of the exposure-outcome relationship, including
confounding by indication. For example, our instrumental
variable analysis would not suffer from bias if GPs were
more likely to offer varenicline to patients they believed
were more likely to quit, or were more supportive to these
patients during their quit attempt or if a patient prescribed
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Figure 3. The effectiveness of varenicline stratified by socioeconomic
position. Partial adjusted odds ratios and 95% confidence intervals for
the association of prescription of varenicline versus NRT and smoking
cessation at 3, 6 and 9 months and 1, 2 and 4 years after exposure, by
level of deprivation as measured by the Index of Multiple Deprivation
Score (IMD). IMD is an increasing measure of neighbourhood disadvan-
tage; models were adjusted for age, sex and year of first prescription.
Missing IMD values were not imputed and patients with missing IMD
data were excluded from all analyses, to ensure comparability of results
across samples.
Legend:
h Patients from least deprived areas (IMD scores 1 to 10), N¼ 52 534.
~ Patients from most deprived areas (IMD scores 11 to 20), N¼ 72 247.
Overall  (I−squared = 37.7%, p = 0.170)
Baker et al. 2016
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Figure 4. Random effects meta-analysis comparing effect estimates (odds ratio and 95% confidence interval) from existing studies examining the ef-
fect of varenicline versus NRT for smoking cessation at 6–12 months’ follow–up.
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varenicline had a failed quit attempt using NRT. The in-
strumental variable analysis provides an alternative source
of evidence about the effects of varenicline, using observa-
tional data.24 The instrumental variable results were less
precise, but were consistent with the multivariable adjusted
regression results, and suggested that varenicline was more
effective for smoking cessation.24
This study used prescriptions issued in primary care;
therefore, we do not have any information on medication
adherence, and patients may have taken over-the-counter
stop-smoking medications. Few patients faced a difference in
out-of-pocket costs between varenicline and NRT prescrip-
tions; therefore this is unlikely to have affected adherence.
Furthermore, other studies have found that users of NRT
continue taking the medication less than half the time it is
prescribed.38 This means that our results are estimates of the
effects of prescribing smoking cessation medications, and
may underestimate the effects of actually taking these medi-
cations. Nonetheless, the estimates presented in this study re-
flect the effects of prescribing stop-smoking medications
allowing for real-world patient treatment adherence. Finally,
the diagnostic categories used to define covariates may not
have captured all patients with applicable diagnoses.
However, where possible we used validated code lists.39
Comparison with other studies
A systematic review and network meta-analysis (i.e. a
meta-analysis technique conducted where there a very few
direct comparisons of treatments) has determined the effi-
cacy of varenicline versus NRT for smoking cessation.7
The review found that at 6 to 12 months’ follow-up, par-
ticipants allocated to varenicline were more likely to quit
compared with those allocated to NRT.7 In this study, we
meta-analysed the effect estimates derived from the net-
work meta-analysis reported by Cochrane,7 estimates from
full-scale RCTs3–5,7 and those derived from our study. The
met- analysis indicated that our findings were comparable
to those derived from gold-standard RCTs.32,33
Evidence from The Health Improvement Network indi-
cated that smokers in more deprived groups were more
likely to receive advice to quit from their GP.11 However,
observational studies have shown that smokers from disad-
vantaged backgrounds are much less likely to quit.10,12
Our study found that those from the most deprived areas
were less likely to be prescribed varenicline; but that there
was little evidence of clinically meaningful differences in
the effect of varenicline by SEP.
Conclusion and clinical implications
Patients prescribed varenicline were more likely to quit
smoking compared with those prescribed NRT up to 4
years after prescription, when treated in primary care. The
results from this study provide new evidence that vareni-
cline is not only efficacious (as indicated by RCTs) but is
effective in real-world clinical practice. Taken together,
this evidence may be used to update clinical guidelines on
the use of varenicline for smoking cessation.
Supplementary Data
Supplementary data are available at IJE online.
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